Krzysztof Kałwak

Summary

Country: Poland

Publications

  1. ncbi Posttransplant adoptive immunotherapy with interleukin-2 in children suffering from neuroectodermal tumors with poor prognosis
    K Kałwak
    Department of Pediatric Hematology and Oncology, Medical University of Wrocław, 44 Bujwida Street, 50 345 Wrocław, Poland
    Transplant Proc 34:665-7. 2002
  2. ncbi Late-onset idiopathic thrombocytopenic purpura correlates with rapid B-cell recovery after allogeneic T-cell-depleted peripheral blood progenitor cell transplantation in children
    K Kalwak
    Department of Pediatric Hematology and Oncology, Medical University of Wroclaw, Wroclaw, Poland
    Transplant Proc 34:3374-7. 2002
  3. ncbi Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in
    Krzysztof Kałwak
    Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Poland
    Biol Blood Marrow Transplant 16:1388-401. 2010
  4. ncbi A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors
    K Kalwak
    Department of Pediatric Hematology and Oncology, Medical University of Wroclaw, Wroclaw, Poland
    Transplant Proc 35:1551-5. 2003
  5. ncbi Clinical value of the flow cytometric method for measuring lymphocyte subset activation: spontaneous activation of T-cell subpopulations is associated with acute GvHD
    K Kalwak
    Department of Pediatric Hematology and Oncology, Medical University of Wroclaw, Wroclaw, Poland
    Transplant Proc 35:1559-62. 2003
  6. ncbi Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors
    Krzysztof Kalwak
    Department of Pediatric Hematology Oncology, University School of Medicine, Wroclaw, 50 345 Wroclaw, Poland
    J Interferon Cytokine Res 23:173-81. 2003
  7. ncbi Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative?
    K Kalwak
    Department of Pediatric Hematology Oncology, Wroclaw University of Medicine, Wroclaw, Poland
    Transplant Proc 36:1574-7. 2004
  8. ncbi Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma
    Katarzyna Drabko
    BMT Unit, Department of Pediatric Hematology and Oncology, Children s University Hospital, Lublin, Poland
    Pediatr Transplant 9:618-21. 2005
  9. pmc PCR diagnostics and monitoring of adenoviral infections in hematopoietic stem cell transplantation recipients
    Iwona Bil-Lula
    Department of Clinical Chemistry, University of Medicine in Wrocław, ul Pasteura 2, 50 367 Wrocław, Poland
    Arch Virol 155:2007-15. 2010
  10. ncbi [Analysis of some risk factors for abnormal growth velocity in children treated with haematopoetic stem cell transplantation]
    Dorota Wojcik
    Klinika Transplantacji Szpiku, Onkologii i Hematologii Dzieciecej, Ul Bujwida 44, 50 345 Wrocław, Poland
    Med Wieku Rozwoj 10:841-8. 2006

Collaborators

Detail Information

Publications12

  1. ncbi Posttransplant adoptive immunotherapy with interleukin-2 in children suffering from neuroectodermal tumors with poor prognosis
    K Kałwak
    Department of Pediatric Hematology and Oncology, Medical University of Wrocław, 44 Bujwida Street, 50 345 Wrocław, Poland
    Transplant Proc 34:665-7. 2002
  2. ncbi Late-onset idiopathic thrombocytopenic purpura correlates with rapid B-cell recovery after allogeneic T-cell-depleted peripheral blood progenitor cell transplantation in children
    K Kalwak
    Department of Pediatric Hematology and Oncology, Medical University of Wroclaw, Wroclaw, Poland
    Transplant Proc 34:3374-7. 2002
  3. ncbi Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in
    Krzysztof Kałwak
    Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Poland
    Biol Blood Marrow Transplant 16:1388-401. 2010
    ..The study findings may be limited to the population of patients receiving in vivo T cell depletion, which is now broadly used in unrelated donor setting in Europe...
  4. ncbi A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors
    K Kalwak
    Department of Pediatric Hematology and Oncology, Medical University of Wroclaw, Wroclaw, Poland
    Transplant Proc 35:1551-5. 2003
    ..Due to improved immune reconstitution, in spite of an increased risk of GvHD, non-TCD transplants from single HLA-mismatched family donors remain a valuable option for children without matched donors...
  5. ncbi Clinical value of the flow cytometric method for measuring lymphocyte subset activation: spontaneous activation of T-cell subpopulations is associated with acute GvHD
    K Kalwak
    Department of Pediatric Hematology and Oncology, Medical University of Wroclaw, Wroclaw, Poland
    Transplant Proc 35:1559-62. 2003
    ..Thus in future immunosuppressive therapy may be adjusted according to the proportion of activated Ts cells...
  6. ncbi Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors
    Krzysztof Kalwak
    Department of Pediatric Hematology Oncology, University School of Medicine, Wroclaw, 50 345 Wroclaw, Poland
    J Interferon Cytokine Res 23:173-81. 2003
    ..Despite enhanced NK activity, relapses occurred frequently, which might have been due to increased CD94 activation and a poor response from the cytotoxic NK T cells and CD8+ CD57+ T cells...
  7. ncbi Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative?
    K Kalwak
    Department of Pediatric Hematology Oncology, Wroclaw University of Medicine, Wroclaw, Poland
    Transplant Proc 36:1574-7. 2004
    ..Splenectomy prior to HCT may positively affect the posttransplant course in patients with overt splenomegaly for example those afflicted with JMML...
  8. ncbi Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma
    Katarzyna Drabko
    BMT Unit, Department of Pediatric Hematology and Oncology, Children s University Hospital, Lublin, Poland
    Pediatr Transplant 9:618-21. 2005
    ..New approaches such as anti-tumor vaccination or using of imatinib are reasonable to introduce in patients with relapsed or resistant to therapy Ewing's tumor...
  9. pmc PCR diagnostics and monitoring of adenoviral infections in hematopoietic stem cell transplantation recipients
    Iwona Bil-Lula
    Department of Clinical Chemistry, University of Medicine in Wrocław, ul Pasteura 2, 50 367 Wrocław, Poland
    Arch Virol 155:2007-15. 2010
    ..This study also showed a strong interaction between co-infections of AdV and BK polyomavirus in patients undergoing hematopoietic stem cell transplantations...
  10. ncbi [Analysis of some risk factors for abnormal growth velocity in children treated with haematopoetic stem cell transplantation]
    Dorota Wojcik
    Klinika Transplantacji Szpiku, Onkologii i Hematologii Dzieciecej, Ul Bujwida 44, 50 345 Wrocław, Poland
    Med Wieku Rozwoj 10:841-8. 2006
    ..Late effects following haematopoietic stem cell transplantation occur both in children and adults. Endocrine impairment may cause abnormal growth velocity and impaired growth in children...
  11. ncbi Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children
    E Gorczynska
    Department of Pediatric Oncology and Hematology, Wroclaw University of Medicine, 44 Bujwida Street, PL50 345 Wroclaw, Poland
    Bone Marrow Transplant 33:211-7. 2004
    ..A total of 10 patients are alive in remission with median follow-up of 338 days. Our results support the hypothesis that chimerism-guided immunotherapy after alloHCT may prevent progression to hematological relapse...
  12. ncbi PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13)
    S Strehl
    1CCRI, Children s Cancer Research Institute, St Anna Kinderspital, Kinderspitalgasse 6, A 1090 Vienna, Austria
    Leukemia 17:1121-3. 2003
    ..As the PAX5 and ETV6 genes are localized at 9p13 and 12p13, respectively, the cytogenetic description of the dic(9;12)-PAX5/ETV6 rearrangement should be refined to dic(9;12)(p13;p13)...